Sun Pharma, Dr. Reddy’s Laboratories, Aurobindo Pharma, and Jubilant Pharma recall products in the US market :
Sun Pharma, Aurobindo Pharma, Dr. Reddy’s Laboratories, and Jubilant Pharma have begun to recall products in the US market. These companies initiated the aforementioned action due to various reasons.
The USFDA’s latest Enforcement report stated that Sun Pharma is recalling Cequa ophthalmic solution. This ophthalmic solution treats chronic dry eyes. The US–based subsidiary of this company has initiated a nationwide recall of over 37,400 cartons of this product for being” sub potent. “ Each carton has around 60 vials of the ophthalmic solution. The Princeton ( NJ ) based firm started this action on 22 February 2021.
Dr. Reddy’s Laboratories recalls Atorvastatin calcium tablets
Dr. Reddy’s Laboratories has also been recalling Atorvastatin calcium tablets in the US market. Over 10,440 ( 90 – count ) and 2,24,710 ( 500 count ) bottles of this tablet is being recalled. This drug is used for the prevention of cardiovascular disease. This recall was due to “ failed impurities/degradation specification “ and was initiated on 19 February 2021. The USFDA categorized this as a Class III recall initiated when the exposure to or using a violative product is not likely to cause adverse health effects. Read about Atorvastatin- What are the indications and popular brands?
The drug firm is also recalling over 16,449 bottles of Progesterone capsules ( 200 mg ). In the US, This product causes menstrual periods in women who have not yet reached menopause. “ failed dissolution specifications.” is the reason for this product recall. 1
The nationwide recall of this lot of the product was initiated on 26 February 2021. This was classified as Class II recall by the USFDA. This type of recall occurs due to the use of or exposure to a violative product that may cause temporary or medically reversible adverse effects. This recall is also put into action when the probability of serious adverse health consequences is remote.
Aurobindo Pharma initiated a recall of Famotidine tablets.
Aurobindo Pharma also initiated a nationwide recall of over 1,296 bottles of Famotidine tablets on 20 January 2021. These tablets were recalled due to the presence of foreign tablets in the lot of famotidine 40 mg. The foreign tablets present in the lot were famotidine 20 mg and ibuprofen 400 mg tablets. This recall was also categorized as a Class II recall. Read Famotidine-Pharmacology and popular brands.
Another pharma company that initiated a nationwide recall is Jubilant Cadista Pharmaceuticals. This pharma company received a customer complaint of a misaligned print of the printed dosing instructions on the blister card of its product. This product is called Methylprednisolone tablets that are prescribed for their anti-inflammatory and immunosuppressive effect.
It was recalled in the American market due to an “ illegible label “. This action was initiated on 19 February 2021 and has been classified as a Class III recall.
Jubilant Cadista Pharma is a subsidiary of Singapore – based Jubilant Pharma. The latter is a wholly –owned subsidiary of Noida – based Jubilant Life Sciences.
- 1. United States Food and Drug Administration
- 2. New Jersey